Last $140.00 USD
Change Today +3.08 / 2.25%
Volume 1.4M
As of 4:15 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

Transactions by VALEANT PHARMACEUTICALS INTE (VRX) in the last 6 months

Announced 11/20/14
Valeant Pharmaceuticals International, Inc.
Buyback

Valeant Pharmaceuticals International, Inc. (TSX:VRX) announces a share repurchase program. Under the program, the company will repurchase up to $2,000 million worth of its common shares, senior notes and/or other debt or shares that may be issued prior to the completion of the program. The repurchases of common shares will be made at prevailing market prices of such shares on the NYSE or the TSX, as the case may be, at the time of the acquisition and will be made in ...
Read More


VRX's price was unchanged after the transaction was announced on 11/20/14.
 
Announced 11/17/14
20.00M for NicOx Inc.
Merger/Acquisition

Valeant Pharmaceuticals International, Inc. (TSX:VRX) acquired Nicox Inc. from Nicox SA (ENXTPA:COX) for $20 million in cash on November 17, 2014. Valeant has acquired Nicox Inc. for $10 million in cash, plus further cash payments of up to $10 million based upon Valeant achieving certain sales targets with the transferred products. Valeant has acquired most of the Nicox commercial infrastructure in the US associated with diagnostics, while Nicox has retained a number ...
Read More


VRX's price was unchanged after the transaction was announced on 11/17/14.
Investor / Buyer
Valeant Pharmaceuticals International, Inc.
Creditor / Lender
Nicox SA
 
Announced 09/23/14
CROMA-PHARMA GmbH, Ophthalmology and Orthopaedics Divisions
Merger/Acquisition

Valeant Pharmaceuticals International, Inc. (TSX:VRX) entered into an agreement to acquire ophthalmology and orthopaedics divisions from CROMA-PHARMA GmbH on September 22, 2014. As announced on November 4, 2014, Bausch & Lomb Canada Inc. completed the acquisition of CROMA Pharma Canada LTD from CROMA-PHARMA GmbH. Wolfgang Kinner, Jakob Pommer, Andreas W. Mayr and Jürgen Kittel of Dorda Brugger Jordis Rechtsanwälte GmbH acted as legal advisors for CROMA-PHARMA.


VRX's price was unchanged after the transaction was announced on 09/23/14.
Investor / Buyer
Bausch & Lomb Canada Inc.
Valeant Pharmaceuticals International, Inc.
Creditor / Lender
CROMA-PHARMA GmbH
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $140.00 USD +3.08

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $260.90 USD +4.38
Astellas Pharma Inc ¥1,654 JPY -12.50
Mylan Inc/PA $55.26 USD +1.70
Shire PLC 4,522 GBp +32.00
Sun Pharmaceutical Industries Ltd 811.35 INR -18.80
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 93.4x
Price/Sales 5.8x
Price/Book 9.0x
Price/Cash Flow 24.4x
TEV/Sales 3.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.